Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer's Disease Spectrum.
Nilsson NIV, Picard C, Labonté A, Köbe T, Meyer PF, Villeneuve S, Auld D, Poirier J, For The Prevent-Ad Research Group, Alzheimer's Disease Neuroimaging Initiative. Nilsson NIV, et al. Among authors: kobe t. Genes (Basel). 2021 Nov 17;12(11):1805. doi: 10.3390/genes12111805. Genes (Basel). 2021. PMID: 34828411 Free PMC article.
Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease.
Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group. Pichet Binette A, et al. Biol Psychiatry. 2021 Apr 15;89(8):776-785. doi: 10.1016/j.biopsych.2020.01.023. Epub 2020 Feb 6. Biol Psychiatry. 2021. PMID: 32228870 Free PMC article.
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, Provost K, Soucy JP, Buckley RF, Benzinger TLS, Morris JC, Villemagne VL, Doré V, Sperling RA, Johnson KA, Rowe CC, Gordon BA, Poirier J, Breitner JCS, Villeneuve S; PREVENT-AD, HABS, and AIBL Research Groups. Strikwerda-Brown C, et al. JAMA Neurol. 2022 Oct 1;79(10):975-985. doi: 10.1001/jamaneurol.2022.2379. JAMA Neurol. 2022. PMID: 35907254 Free PMC article.
Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H, Pichet Binette A, Köbe T, Meyer PF, Gonneaud J, St-Onge F, Provost K, Soucy JP, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative, the Harvard Aging Brain Study, the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease Research Group. Ozlen H, et al. Among authors: kobe t. JAMA Neurol. 2022 Oct 1;79(10):1025-1035. doi: 10.1001/jamaneurol.2022.2442. JAMA Neurol. 2022. PMID: 35994280 Free PMC article.
Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Meyer PF, et al. Among authors: kobe t. Ann Neurol. 2022 Apr;91(4):548-560. doi: 10.1002/ana.26308. Epub 2022 Feb 18. Ann Neurol. 2022. PMID: 35084051
Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use.
Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. JAMA Netw Open. 2020 Feb 5;3(2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780. JAMA Netw Open. 2020. PMID: 32031648 Free article.
Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular risk factors and functional connectivity changes.
Köbe T, Binette AP, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Köbe T, et al. Neuroimage. 2021 May 1;231:117832. doi: 10.1016/j.neuroimage.2021.117832. Epub 2021 Feb 4. Neuroimage. 2021. PMID: 33549747 Free article.
Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)-study protocol for a randomized controlled trial.
Wirth M, Schwarz C, Benson G, Horn N, Buchert R, Lange C, Köbe T, Hetzer S, Maglione M, Michael E, Märschenz S, Mai K, Kopp U, Schmitz D, Grittner U, Sigrist SJ, Stekovic S, Madeo F, Flöel A. Wirth M, et al. Among authors: kobe t. Alzheimers Res Ther. 2019 May 1;11(1):36. doi: 10.1186/s13195-019-0484-1. Alzheimers Res Ther. 2019. PMID: 31039826 Free PMC article. Clinical Trial.
Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer's disease.
Gaubert M, Lange C, Garnier-Crussard A, Köbe T, Bougacha S, Gonneaud J, de Flores R, Tomadesso C, Mézenge F, Landeau B, de la Sayette V, Chételat G, Wirth M. Gaubert M, et al. Among authors: kobe t. Alzheimers Res Ther. 2021 Jan 18;13(1):29. doi: 10.1186/s13195-020-00759-3. Alzheimers Res Ther. 2021. PMID: 33461618 Free PMC article.
41 results